French drugmaker Ipsen (Euronext: IPN) and new startup PeptiMimesis have announced a new partnership to develop a novel generation of therapeutic peptides targeting membrane receptors which are overexpressed in a large number of cancers.
Only last month PeptiMimesis formally launched its activities to develop the new therapeutic peptides using a breakthrough technology from the University of Strasbourg and INSERM (the French Institute of Health and Medical Research).
Now it has agreed a research deal with Ipsen and a licensing option allowing the company to develop and market new drug candidates which come from the partnership.
The deal seeks to combine Ipsen’s expertise in peptide design and development with PeptiMimesis’ knowledge in identifying transmembrane peptides and intracellular signalling.
The target receptor is involved in various phases of cancer development, including angiogenesis, immune tolerance and proliferation.
Read more: http://www.thepharmaletter.com/article/ipsen-and-new-biotech-startup-announce-oncology-partnership